We are live on ! Find out more
MTR

Mesa Royalty Trust

14 hedge funds and large institutions have $3.02M invested in Mesa Royalty Trust in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.31% less ownership

Funds ownership: 11.41%10.1% (-1.3%)

18% less funds holding

Funds holding: 1714 (-3)

35% less capital invested

Capital invested by funds: $4.67M → $3.02M (-$1.65M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
3
Reduced
5
Closed
4
Calls
Puts
Net Calls
Net Calls Change

MTR Hedge Fund Activity: Q1 2023 in Review

14 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Mesa Royalty Trust (MTR) for Q1 2023, worth a combined $3.02M — down 35% from $4.67M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of MTR and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 3 added.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $11.8K. The largest seller was Fayez Sarofim & Co, exiting entirely with an estimated $209K sold.

  • 14 institutional investors held Mesa Royalty Trust (MTR) as of Q1 2023, down from 17 in Q4 2022.
  • Funds reported $3.02M of Mesa Royalty Trust stock for Q1 2023, down 35% quarter-over-quarter.
  • 1 fund opened new Mesa Royalty Trust positions in Q1 2023 and 4 closed out, a net change of -3 holders.
  • The largest Mesa Royalty Trust buyer in Q1 2023 was BNP Paribas Financial Markets, an estimated $11.8K added.
  • The largest Mesa Royalty Trust seller in Q1 2023 was Fayez Sarofim & Co, an estimated $209K sold.

Based on aggregated 13F filings for Q1 2023.